AMBUJACEM

reported a 91% year-on-year drop in consolidated net profit to Rs 204 crore for Q3FY26, compared to Rs 2,158 crore a year earlier. However, Q3 net profit normalised to Rs 378 crore, a 258% YoY jump. Volume growth was 2X the industry average with a 31% YoY rise in PMT EBITDA and a margin of 13.2%.